Do IL-5-targeting therapies for asthma have a protective effect in COVID-19 patients with severe asthma who are already receiving these therapies?
There is neither evidence for a protective effect of these biologicals nor a negative effect regarding SARS-CoV-2 infection. Importantly, maintaining proper asthma control is imperative and so is to follow up on severe asthmatics during the COVID-19 pandemic, for example via telemedicine.44